Ongoing, recruitingHuman Pharmacology (Phase I)- OtherInterventional

An open-label, healthy subject, two-part study to assess the effect of verapamil on systemic exposure of EP395 (Part A), and to assess the effect of EP395 on systemic exposure of midazolam and digoxin (Part B)

At a glance

Status

Ongoing, recruiting

Phase

Human Pharmacology (Phase I)- Other

Sponsor

Epiendo Pharmaceuticals ehf., Epiendo Pharmaceuticals ehf.

Enrolment target

Start

26 Sep 2023

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.